论文部分内容阅读
从８０～９０年间共收治乳腺癌病人３９４例，全部女性，单纯手术组３、５、１０年生存率７４．４％、６０．７％、３１．３％。８３～８６前后，随机选取乳腺癌患者术中化疗５７例，３、５、１０年生存率：８９．５％、７５．４％、４９．１％。术后化疗６２例３、５、１０年生存率：８８．７％、７５．８％、４８．４％。结果显示：术中术后化疗５、１０年生存率明显高于单纯组（Ｐ＜０．０１）术中化疗５、１０年生存率和术后化疗组无统计学差异。单纯手术组、术中化疗组、术后化疗组五年复发率２４．８％、１２．２％、１７．７％，结果术中化疗组５年复发率低于术后和单纯手术组，差异有显著性（Ｐ＜０．０５）。临床研究证实，术中化疗对Ⅱ、Ⅲ期乳癌患者的预后复发有重要意义。
From 1980 to 1990, a total of 394 cases of breast cancer patients were treated. All women had a survival rate of 74.4%, 60.7%, and 31.3% for the 3, 5, and 10 years of the surgery alone group. Before and after 83 ~ 86, 57 patients were randomly selected for intraoperative chemotherapy for breast cancer. The survival rates at 3, 5, and 10 years were 89.5%, 75.4%, and 49.1%. Postoperative chemotherapy in 62 cases of 3,5,10 years survival rate: 88.7%, 75.8%, 48.4%. The results showed that the 5-year and 10-year survival rates of intraoperative and postoperative chemotherapy were significantly higher than those of the simple group (P<0.01). The 5-year and 10-year survival rates of intraoperative chemotherapy and postoperative chemotherapy groups were not statistically different. The five-year recurrence rates in the surgery alone group, the intraoperative chemotherapy group, and the postoperative chemotherapy group were 24.8%, 12.2%, and 17.7%. The 5-year recurrence rate of the intraoperative chemotherapy group was lower than that of the postoperative and surgery alone group. The difference was significant (P < 0.05). Clinical studies have confirmed that intraoperative chemotherapy has important implications for the prognosis of patients with stage II and stage III breast cancer.